Related Experiment Video
Updated: Feb 25, 2026
07:50
Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
Published on: July 16, 2012
14.8K
Investigational drugs in systemic vasculitis
Adrien Mirouse1,2,3,4, Patrice Cacoub1,2,3,4, Anne Claire Desbois1,2,3,4
1a Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biothérapie (DHU i2B) , Sorbonne Universités , UPMC Université Paris 06, UMR 7211 , Paris , France.
Expert Opinion on Investigational Drugs
|August 1, 2017
Summary
New investigational drugs show promise for treating systemic vasculitis, potentially reducing reliance on long-term glucocorticoids and improving patient outcomes. These novel therapies aim for earlier response and lower relapse rates in conditions like ANCA-associated vasculitis.
Area of Science:
- Rheumatology and Immunology
- Clinical Pharmacology
Background:
- Systemic vasculitis treatment relies on glucocorticoids (GC) and immunosuppressants.
- Current therapies face challenges with delayed response, relapse risk, and long-term toxicity.
- Unmet needs include faster onset, targeted treatments, and reduced GC/immunosuppressant side effects.
Purpose of the Study:
- To review investigational drugs in early-phase clinical trials for vasculitis remission induction.
- To focus on ANCA-associated vasculitis, Behçet's disease, giant cell arteritis, Takayasu arteritis, and cryoglobulinemic vasculitis.
- To identify emerging therapeutic targets and their potential benefits.
Main Methods:
- Comprehensive literature review of PubMed articles.
- Systematic review of clinical trials registered on clinicaltrials.gov.
- Analysis of early-phase clinical trial data for investigational vasculitis therapies.
Main Results:
- Several investigational drugs are under evaluation for vasculitis treatment.
- Promising early results suggest potential for glucocorticoid-sparing effects.
- Emerging therapies may reduce relapse rates and offer improved safety profiles.
Conclusions:
- Advances in understanding vasculitis pathogenesis reveal new therapeutic targets.
- Investigational drugs show promise for improved efficacy and safety.
- Further validation in large-scale Phase III studies is essential to confirm these findings.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
602
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
602
01:29Inflammatory Bowel Disease IV: Pharmacological Management
852
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
852
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
546
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
546
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
646
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
646
01:23Antihypertensive Drugs: Vasodilators
2.3K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.3K
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
376
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
376